🏛️ Verified NIH Record • Updated 2026-05-18
Feasibility Study of a Remote Behavioral Dietary Intervention in Patients With Early to Intermediate AMD: Glucose Lowering for Vision Extension (NCT07605468)
Nonrandomized, Unmasked Feasibility Study of a Remote-based Behavioral Dietary Intervention in Patients With Early to Intermediate AMD: Glucose Lowering for Vision Extension (GLOVE)
🟡 Not Yet Recruiting Observational / Diagnostic 🧠 Behavioral & Psychological Program Sponsor: Stanford University
🩺 Plain-English Summary (8th-Grade Level)
The primary goal of the study is to test dietary intervention at glycemic control and carotenoid levels in participants with intermediate age-related macular degeneration.
Who can join: Review the eligibility criteria below.
Location: University of California, Los Angeles — Los Angeles, California
Age range: 55 Years to 75 Years
🧪 Interventions in This Study
- Low glycemic Mediterranean diet behavioral modification (BEHAVIORAL)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of California, Los Angeles — Los Angeles, California
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Age-Related Macular Degeneration
- A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders — Springfield, Illinois
- Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration — San Francisco, California
- ForeseeHome NRich Registry — Toms River, New Jersey
- Impact of Non-Exudative Type 1 MNV on AMD Progression — Salt Lake City, Utah
- A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration — Phoenix, Arizona
- Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration — Scottsdale, Arizona
Explore by condition: All Age-Related Macular Degeneration clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.